Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK7 | Q8TDX7 | 16/20 | 0.53 |
| ▸ | FLT3 | P36888 | 2/20 | 0.51 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | YES1 | P07947 | 1/20 | 0.43 |
| ▸ | LYN | P07948 | 1/20 | 0.43 |
| ▸ | HCK | P08631 | 1/20 | 0.43 |
| ▸ | FGR | P09769 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | BLK | P51451 | 1/20 | 0.43 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25818014 | 0.93 | NEK7 (0.55) | NEK7KDRABL1HCKSRC | |
| SCHEMBL24096471 | 0.91 | NEK7 (0.64) | NEK7FLT3 | |
| SCHEMBL30320473 | 0.91 | NEK7 (0.64) | NEK7FLT3 | |
| SCHEMBL25817974 | 0.89 | FLT3 (0.57) | NEK7FLT3RETKDRABL1 | |
| SCHEMBL25818030 | 0.88 | NEK7 (0.64) | NEK7FLT3RET | |
| SCHEMBL25793563 | 0.86 | FLT3 (0.69) | NEK7FLT3 | |
| SCHEMBL30486149 | 0.84 | NEK7 (0.59) | NEK7KDRLCKSRC | |
| SCHEMBL24096596 | 0.84 | NEK7 (0.59) | NEK7KDRLCKSRC | |
| SCHEMBL25793482 | 0.84 | NEK7 (0.58) | NEK7KDRLCKSRC | |
| SCHEMBL30320563 | 0.83 | NEK7 (0.66) | NEK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | NEK7, NEK1, NEK5 | NEK7 1/4885FLT3 886/4885RET 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.